Cytarabine (U-19920A) - Moligand™, 10mM in Water , DNA polymerase (alpha/delta/epsilon) inhibitor, CAS No.147-94-4, DNA polymerase (alpha/delta/epsilon) inhibitor

CAS: 147-94-4 Cat. No.: C408830 Molecular Weight: 243.22 Beilstein Registry Number: 89175 EC Number: 205-705-9

GRADE & PURITY Moligand™, 10mM in Water

Synonyms

Cytarabin, Ara-C, Arabinofuranosyl Cytidine, Cytosine β-D-arabinofuranoside, Cytosine arabinoside, NSC 63878, NSC 287459 | 4-amino-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

Information

Cytarabine (U-19920A) Cytarabine (U-19920A， Cytarabin, Ara-C, Arabinofuranosyl Cytidine, Cytosine β-D-arabinofuranoside, Cytosine arabinoside, NSC 63878, NSC 287459) is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type C
In vitro

Cytarabine (AraC) is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC50 of 16 nM. Increasing concentrations of Cytarabine (IC50 of 0.69 μM) results in decreased metabolic activity of sensitive rat leukemic cell line RO/1, and the cell toxity can be highly enhanced by transfection with human wt dCK (IC50 of 0.037 μM) but not the inactive, alternatively spliced dCK forms. Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μM, of which 100 μM shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion.

In vivo

Cytarabine is highly effective against acute leukaemias, which causes the characteristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man. Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity.
Cell Data

cell lines：

Concentrations：~100 μM

Incubation Time：24, 48 and 72 hours

Powder Purity:≥99%

Specifications

Synonyms

Cytarabin, Ara-C, Arabinofuranosyl Cytidine, Cytosine β-D-arabinofuranoside, Cytosine arabinoside, NSC 63878, NSC 287459 | 4-amino-1-((2R, 3S, 4S, 5R)-3, 4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

Specifications & Purity

Moligand™, 10mM in Water

Biochemical and Physiological Mechanisms

Cytarabine (U-19920A， Cytarabin, Ara-C, Arabinofuranosyl Cytidine, Cytosine β-D-arabinofuranoside, Cytosine arabinoside, NSC 63878, NSC 287459) is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells. Cytarabin

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Grade

Moligand™

Action Type

INHIBITOR

Mechanism of action

DNA polymerase (alpha/delta/epsilon) inhibitor

Product Properties

• ALogP: -2.1

Names and Identifiers

• Isomeric SMILES: C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O
• WGK Germany: 3
• RTECS: HA5425000
• Molecular Weight: 243.22
• Beilstein: 89175
• Reaxy-Rn: 753984
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=753984&ln=

Associated Targets(Human)

MDM2 Tchem E3 ubiquitin-protein ligase Mdm2 (1 Activities)

Discover Target: MDM2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Chemical and Physical Properties

• Specific Rotation[α]: 158 ° (C=1, H2O)
• Melt Point(°C): 214°C

References

1. Qiankun Quan, Xinxin Ma, Ming Li, Xi Li, Haifeng Yuan.  (2023)  Ginsenoside Rg1 promotes β‑amyloid peptide degradation through inhibition of the ERK/PPARγ phosphorylation pathway in an Alzheimer's disease neuronal model.  Experimental and Therapeutic Medicine,  27  (1): (1-13).  [PMID:38125359] [10.3892/etm.2023.12319]

2. Yue-Ming Yu, Fan-Zhi Bu, Su-Su Meng, Cui-Wei Yan, Zhi-Yong Wu, Yan-Tuan Li.  (2023)  The first nano-cocrystal formulation of marine drug cytarabine with uracil based on cocrystal nanonization strategy for long-acting injection exhibiting enhanced antitumor activity.  INTERNATIONAL JOURNAL OF PHARMACEUTICS,      [PMID:37567370] [10.1016/j.ijpharm.2023.123300]

3. Lejiao Jia, Huatian Yang, Dandan Zheng, Jingjing Ye, Qian Zhou, Genjv Li, Ying Zhou, Xinyu Yang, Jinting Liu, Feng Ye, Yuliang Song, Daoxin Ma, Chunyan Ji.  (2023)  Smart and Generalizable Cytarabine Derivative-Triggered Nanoparticles for Synergistic Therapy of Relapsed/Refractory Acute Myeloid Leukemia.  ACS Applied Materials & Interfaces,      [PMID:37249260] [10.1021/acsami.3c03632]

4. Siyu Wang, Lutong Wang, Jingwen Xu, Yihai Wang, Limin Xiang, Xiangjiu He.  (2023)  Synergistic Combination of the Total Steroidal Saponins from the Berries of Black Nightshade and Adriamycin to Overcome Leukemia Multidrug Resistance.  JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY,      [PMID:36752041] [10.1021/acs.jafc.2c07740]

5. Wang Pengwei, Mao Senlin, Yi Tingting, Wang Lihua.  (2022)  LncRNA MALAT1 Targets miR-9-3p to Upregulate SAP97 in the Hippocampus of Mice with Vascular Dementia.  BIOCHEMICAL GENETICS,  61  (3): (916-930).  [PMID:36227424] [10.1007/s10528-022-10289-2]

6. Jie Zhao, Yue Wu, Shanshan Liang, Xiangyu Piao.  (2022)  Activation of SSAT1/ALOX15 Axis Aggravates Cerebral Ischemia/Reperfusion Injury via Triggering Neuronal Ferroptosis.  NEUROSCIENCE,      [PMID:35090880] [10.1016/j.neuroscience.2022.01.017]

7. Dan Shao, Qiang Gao, Yanshan Sheng, Shangji Li, Yong Kong.  (2022)  Construction of a dual-responsive dual-drug delivery platform based on the hybrids of mesoporous silica, sodium hyaluronate, chitosan and oxidized sodium carboxymethyl cellulose.  INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,      [PMID:35033530] [10.1016/j.ijbiomac.2022.01.033]

8. Lefeng Liu, Zhiguo Xu, Yang Liu, Zheng-Zhi Yin, Yanshan Sheng, Chengqiang Ding, Yong Kong.  (2021)  Facile synthesis of calcium carbonate/polyacrylic acid hydrogels for pH-responsive delivery of cytarabine.  Journal of Saudi Chemical Society,      [PMID:] [10.1016/j.jscs.2021.101344]

9. Yuzhe Chen, Wenxuan Zhao, Honglian Dai.  (2021)  Porous PLGA-PEG nerve conduit decorated with oriented electrospun chitosan-RGD nanofibre.  Journal of Materials Research and Technology-JMR&T,      [PMID:] [10.1016/j.jmrt.2021.07.117]

10. Kai Chen, Yong Qian, Chaoyang Wang, Dongjie Yang, Xueqing Qiu, Bernard P. Binks.  (2021)  Tumor microenvironment-responsive, high internal phase Pickering emulsions stabilized by lignin/chitosan oligosaccharide particles for synergistic cancer therapy.  JOURNAL OF COLLOID AND INTERFACE SCIENCE,      [PMID:33618293] [10.1016/j.jcis.2021.02.012]

11. Qiang Gao, Jun Gao, Chengqiang Ding, Shangji Li, Linhong Deng, Yong Kong.  (2020)  Construction of a pH- and near-infrared irradiation-responsive nanoplatform for chemo-photothermal therapy.  INTERNATIONAL JOURNAL OF PHARMACEUTICS,      [PMID:33259903] [10.1016/j.ijpharm.2020.120112]

12. Yanshan Sheng, Wei Dai, Jun Gao, Hongda Li, Wensheng Tan, Jingwei Wang, Linhong Deng, Yong Kong.  (2020)  pH-sensitive drug delivery based on chitosan wrapped graphene quantum dots with enhanced fluorescent stability.  Materials Science & Engineering C-Materials for Biological Applications,      [PMID:32409046] [10.1016/j.msec.2020.110888]

13. Zhigang Fang, Xiaozhen Wang, Yanling Sun, Ruifang Fan, Zhong Liu, Rui Guo, Deming Xie.  (2019)  Sgc8 aptamer targeted glutathione-responsive nanoassemblies containing Ara-C prodrug for the treatment of acute lymphoblastic leukemia.  Nanoscale,  11  (47): (23000-23012).  [PMID:31769777] [10.1039/C9NR07391D]

14. Jing Liu, Dujuan Zhao, Wenxiu He, Huiyuan Zhang, Zhonghao Li, Yuxia Luan.  (2016)  Nanoassemblies from amphiphilic cytarabine prodrug for leukemia targeted therapy.  JOURNAL OF COLLOID AND INTERFACE SCIENCE,      [PMID:27776282] [10.1016/j.jcis.2016.10.041]

15. Jing Liu, Jing Liu, Dujuan Zhao, Naxin Ma, Yuxia Luan.  (2016)  Highly enhanced leukemia therapy and oral bioavailability from a novel amphiphilic prodrug of cytarabine.  RSC Advances,  6  (42): (35991-35999).  [PMID:] [10.1039/C6RA02051H]

16. Xuelei Wang, Xiaowei Wang, Jiayi Su, Dan Wang, Wenkai Feng, Xiaobo Wang, Hongwei Lu, Apeng Wang, Mingliang Liu, Guimin Xia.  (2024)  A Dual-Function LipoAraN-E5 Coloaded with N4-Myristyloxycarbonyl-1-β-d-arabinofuranosylcytosine (AraN) and a CXCR4 Antagonistic Peptide (E5) for Blocking the Dissemination of Acute Myeloid Leukemia.  ACS Nano,      [PMID:39364559] [10.1021/acsnano.4c05079]

17. Yan Shi, Yufeng Yang, Juntong Liu, Jinling Zheng.  (2024)  Avicularin Treatment Ameliorates Ischemic Stroke Damage by Regulating Microglia Polarization and its Exosomes via the NLRP3 Pathway.  Journal of Integrative Neuroscience,  23  (11): (196).  [PMID:39613475] [10.31083/j.jin2311196]

18. Yijun Jia, Zhao Zhao, Leyang Chen, Yongqi Liu, Bin Zhu.  (2025)  Carbon Nanotube-Based Drug Delivery System Increases Drug Content and Promotes Immune Response in Mandarin Fish.  Fishes,  10  (3): (92).  [PMID:] [10.3390/fishes10030092]

19. Liu Xiaoyu, Yang Lin, Guan Kunping, Chen Zhen, Yang Hua.  (2024)  CSE1L Silencing Enhances Cytarabine-mediated Cytotoxicity in Acute Myeloid Leukemia.  Indian Journal of Hematology and Blood Transfusion,      [PMID:39469152] [10.1007/s12288-024-01773-3]

20. Lanxin Li, Yang Zhang, Zhengqian Chen, Can Xu, Zhongqiu Xu, Haitao Pei, Wei Wang, Ruyong Yao, Cui Hao.  (2024)  Cytarabine prevents neuronal damage by enhancing AMPK to stimulate PINK1 / Parkin-involved mitophagy in Parkinson's disease model.  EUROPEAN JOURNAL OF PHARMACOLOGY,      [PMID:38880222] [10.1016/j.ejphar.2024.176743]

21. Yue-Ming Yu, Xue-Jie Li, Fan-Zhi Bu, Zhi-Long Zhao, Zhi-Yong Wu, Yan-Tuan Li.  (2024)  Drug–Drug Cocrystal Alloy and Nanoformulation of Cytarabine: Optimized Biopharmaceutical Property and Synergistic Antitumor Efficacy.  MOLECULAR PHARMACEUTICS,      [PMID:39392428] [10.1021/acs.molpharmaceut.4c00733]

22. Yao Zuo, Hongwen Li, Xiaochao Wang, Yejin Liang, Caihong Huang, Guanye Nai, Jingrong Ruan, Wenzheng Dong, Xiang Lu.  (2024)  Inhibition of JAK/STAT3 Expression by Acute Myeloid Leukemia-Targeted Nanoliposome for Chemotherapy Enhancement.  ACS Omega,      [PMID:39281932] [10.1021/acsomega.4c00710]

23. Guangchao Xie, Bingjie Li, Shuyue Guo, Wenjing Hou, Yao Wang, Jiamei Liu, Jialin Zhu, Luchen Chang, Xiaoqing Wang, Xiaoyi Wang, Jinbin Pan, Xi Wei.  (2025)  Minimalistic Implant for Percutaneous Magnetic Hyperthermia-Based Combination Therapy of Hepatocellular Carcinoma.  ACS Applied Materials & Interfaces,      [PMID:39916295] [10.1021/acsami.4c18486]

24. Guangchao Xie, Bingjie Li, Xuejun Zhang, Jiaojiao Yu, Shao-Kai Sun.  (2024)  One-Minute Preparation of Iron Foam-Drug Implant for Ultralow-Power Magnetic Hyperthermia-Based Combination Therapy of Tumors in Vivo.  Advanced Science,  11  (11): (2307823).  [PMID:38164827] [10.1002/advs.202307823]

25. Yadong Tang, Boxin Huang, Yuqin Dong, Wenlong Wang, Xi Zheng, Wei Zhou, Kun Zhang, Zhiyun Du.  (2017)  Three-dimensional prostate tumor model based on a hyaluronic acid-alginate hydrogel for evaluation of anti-cancer drug efficacy.  JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION,      [PMID:28583017] [10.1080/09205063.2017.1338502]

26. Shiyi Hong, Pei Peng, Cao Yao, Yutian Huang, Siying Cai, Tongtong Huang, Yulu Ying, Chaofeng Mu.  (2025)  Bone marrow-targeted LOXL2 inhibitor-loaded yolk-shell nanoparticle overcomes extracellular matrix-mediated chemotherapy resistance in acute myeloid leukemia.  INTERNATIONAL JOURNAL OF PHARMACEUTICS,      [PMID:40389070] [10.1016/j.ijpharm.2025.125730]

27. Shiyi Hong, Pei Peng, Yutian Huang, Siying Cai, Cao Yao, Tongtong Huang, Yulu Ying, Wei Li, Yang Xiong, Mancang Gu, Guilin Cheng, Chaofeng Mu.  (2025)  Bone marrow microenvironment-targeted yolk-shell nanoparticle enhances acute myeloid leukemia chemotherapy by preventing endothelial cell/ECM-mediated adhesion.  CHEMICAL ENGINEERING JOURNAL,      [PMID:] [10.1016/j.cej.2025.164084]

28. Xiaoshuang Dai, Daobin Jiang, Chunlin Gou, Ke Mei, Bin Sun, Jianpeng Liu, Na Yao, Xinyu Liu, Neng Qiu.  (2025)  Biotinylated Self-Assembled Cytarabine Nano-Prodrug with Enhanced Targetability and Anticancer Efficacy: An In Vitro Study.  LANGMUIR,      [PMID:40450601] [10.1021/acs.langmuir.5c01147]

29. Huan Cong, Xuejing Hou, Shasha Wang, Jie Pang, Anhua Wang, Kuo Zhang, Jingyu Yang, Chunfu Wu.  (2025)  Tectoridin Derived from Puerariae Flos Alleviates Acute Ethanol-Induced Ataxia in Rats by Targeting the Adenosine A1 Receptor via Its Aglycone.  JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY,      [PMID:41328621] [10.1021/acs.jafc.5c09262]